SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-031908
Filing Date
2024-03-07
Accepted
2024-03-07 16:16:07
Documents
15
Period of Report
2024-03-07
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm248235d1_8k.htm   iXBRL 8-K 58095
2 EXHIBIT 3.1 tm248235d1_ex3-1.htm EX-3.1 7584
  Complete submission text file 0001104659-24-031908.txt   248611

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA otlk-20240307.xsd EX-101.SCH 3304
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20240307_lab.xml EX-101.LAB 34750
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20240307_pre.xml EX-101.PRE 22381
16 EXTRACTED XBRL INSTANCE DOCUMENT tm248235d1_8k_htm.xml XML 3819
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 24730328
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)